Comparative study of efficacy and safety of Administering 4mg once daily and 2mg twice daily of silodosin in patients with benign prostatic hyperplasia
Not Applicable
- Conditions
- benign prostatic hyperplasia
- Registration Number
- JPRN-UMIN000002188
- Lead Sponsor
- JR Tokyo General Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Male
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
1.Men who treated by the medicin that has possibility to influence the urination function 2.prostatic cancer 3.Urinary tract infection 4.urolithiasis 5.hepatic dysfunction, renal dysfunction, cardiac disease 6.orthostatic hypotention 7.Any other clinically relevant laboratory abnormality as judged by the investigator
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change and change rate of I-PSS total score,subscore
- Secondary Outcome Measures
Name Time Method